Právní předpis byl sestaven k datu 18.04.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
SDĚLENÍ
Ministerstva xxxxxxxxxxxx xxxx,
xxxxxx xx mění x xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
Ministerstvo xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 bylo xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx standard Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu.
S xxxxx zněním Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky x prezident xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx změn Xxxxxxx X Českou xxxxxxxxxx.
Xxxx xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X xxx rok 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.
Xxxxxxxx znění Xxxxxxx X xxx xxx 2024 x xxxx xxxxxxx xx xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.
&xxxx;
Xxxxxxx:
x z. XXXx. Xxxxxx, Xx.X., XX.X., x. x.
xxxxxx xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;
Xxxxxxx x. 1
Xxxxxxx xxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx
Xxxx
Xxxxxx xxxxxxxxxx xxxxx a metod xxxxxxx je xxxxxxx Xxxxxxxxxxx standard v xxxxx Světového antidopingového xxxxxxxx.
Xxxxxx xx každoročně xxxxxxxxxxxx po xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx je xxxxxx xx 1. xxxxx 2024.
Xxxxxxxxx text Xxxxxxx zakázaných látek x xxxxx xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx v xxxxxxxxxx x francouzštině. X případě xxxxxxxxxxx xxxxxxxxxxxxx xxxx anglickým x francouzským xxxxxx xxxxxxxxx xxxxx x xxxxxxxxxx.
Xxxx jsou uvedeny xxxxxxx xxxxx používané x xxxxx Xxxxxxx xxxxxxxxxx látek a xxxxx.
Xxxxxxxx Xxx xxxxxxx
Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx jiné xxxxxx, xx xxxxxx Xxx soutěži v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Sportovec xxxxxxxxx, xx xx konce Xxxxxxx x procesu xxxxxx Vzorku.
Zakázané xxxxx
Xx xxxxxxx, xx daná xxxxx xxxx xxxxxx xx xxxxxxxx Při xxxxxxx i Mimo xxxxxx, jak xx xxxxxxxxxx x Xxxxxx.
Xxxxxxxxxx x Xxxxxxxxxxxx
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Xxxxxxxx xxxxx Xxxxxxxxxxxx látkami, x výjimkou těch xxxxxxxxxx x Seznamu xxxxxxxxxx xxxxx x xxxxx dopingu. Žádná Xxxxxxxx metoda xxxxxx Xxxxxxxxxxx xxxxxxx, pokud xxxx x Seznamu xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx metoda.“ Xxxxx xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxx xx xxxx xxxxxxxx xxxx méně xxxxxxxxxx xxx jiné dopingové xxxxx xxxx xxxxxx. Xxx spíše x xxxxx x xxxxxx, xxxxx Sportovec xxxxxxxxxxxxx xxxx nebo xxxxxx x xxxxxx xxxxx xxx ke zlepšení xxxxxxxxxxx xxxxxx.“
Xxxxxxxx xxxxx
Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx látky xxxxxxxxxx jako látky, xxxxx xxxx jako xxxxxx xxxxxxxx x xxxxxx xxxxxx častého xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx sportu. Xxxx Xxxxxxxx látky xxxx označovány xxxx xxxxx: kokain, diamorfin (xxxxxx), methylendioxymetamfetamin (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (THC).
S0 XXXXXXXXXXX XXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX I XXXX XXXXXX)
Xxxxxxx zakázané látky x xxxx xxxxx xxxx Specifické xxxxx.
Xxxxxxxxx xxxxxxxxxxxxxx látka, xx xxxxxx xx nevztahuje xxxxx x xxxxxxxxxxxxx xxxxxx Xxxxxxx x xxxxx xxxx x xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pro xxxxxxx xxxxxxx x xxxx (např. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx vývoji xxxx xxxxxxx vývoj xxx xxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx zakázána xxxxx.
Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) a xxxxxxxxxx xxxxxxxxx (xxxx. Xxxxxxxxxxx x Tirasemtiv).
S1 ANABOLICKÉ XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx zakázané látky x této třídě xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxx xxxxx xxxx zakázány.
S1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)
Xxx exogenním xxxxxx, xxxx xxxx xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol) |
• |
formebolon |
|
|
• |
1-androstenedion (5ɑ-xxxxxxx-1-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxx (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) |
|
|
• |
1-androsteron (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on) |
|
|
• |
4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on) |
• |
metenolon |
|
|
• |
5-androstenedion (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
|
|
• |
7-xxxx-XXXX |
&xxxx;• |
xxxxxxxxxxxxxx |
|
|
• |
11ß-xxxxx-19-xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxx (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (androsta-1,4-dien-3,17-dion) |
• |
oxandrolon |
|
|
• |
calusteron |
• |
oxymesteron |
|
|
• |
klostebol |
• |
oxymetolon |
|
|
• |
danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on) |
• |
testosteron |
|
|
• |
epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
&xxxx;• |
xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX) |
x xxxxx xxxxx s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx.
X1.2. XXXXXXX XXXXXXXXXX XXXXX
Xxxx xxxx xxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx receptorů [XXXX, xxxx. andarin, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, S-23 a XX-11], xxxxxxx x xxxxxxxxxx.
X2 PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX A XXXXXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx v xxxx třídě jsou Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx látky x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky xxxx xxxxxxxx.
X2.1. XXXXXXXXXXXXX (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
X2.1.1 Xxxxxxxx erytropoetinových xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (EPO); sloučeniny xxxxxxxx na XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx sloučeniny, xxxx. XXXX-530, xxxxxxxxxxx.
X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx vyvolávajícího xxxxxxx (XXX), např. xxxxxx; daprodustat (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (FG-4592); xxxxxxxxxx (AKB-6548); xxxxx.
X2.1.3 Xxxxxxxxxx GATA, xxxx. X-11706.
X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (XXX-β), např. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo EPO; xxxxxxxxxxxxx XXX (CEPO).
S2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX FAKTORY
S2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, xxxx xxxx xxxxxx:
• xxxxxxxx xxxxxxxxxxxx (XX),
• xxxxxxxxxxxx xxxxxx (LH),
• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x jeho xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, leuprorelin, nafarelin x xxxxxxxxxxx),
&xxxx;• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.
X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.
X2.2.3 Růstový xxxxxx (XX), jeho analogy x xxxxxxxxx, mimo xxxx xxxxxx:
• analogy xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,
• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176–191.
X2.2.4 Xxxxxxx uvolňující xxxxxxx xxxxxx, mimo xxxx xxxxxx:
• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x jeho xxxxxxx, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x xxxxxxxxxxx,
• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a xxxxxx xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, lenomorelin (ghrelin), xxxxxxxxxxx x xxxxxxxxxxx],
• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. alexamorelin, xxxxxxxxxx (xxxxxxxxx), GHRP-1, XXXX-2 (pralmorelin), GHRP-3, XXXX-4, GHRP-5 a XXXX-6].
X2.3. XXXXXXX FAKTORY X MODULÁTORY XXXXXXXXX XXXXXXX
Xxxx xxxx xxxxxx:
• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)
• xxxxxxx xxxxxx 1 podobný xxxxxxxx (IGF-1, mecasermin) x jeho analogy
• xxxxxxxxxx růstové faktory (XXX)
• růstový xxxxxx xxxxxxxx z krevních xxxxxxxx (PDGF)
• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. XX-500
• vaskulárně-endoteliární xxxxxxx xxxxxx (VEGF)
a xxxxx růstové faktory xxxx modulátory růstových xxxxxxx ovlivňující xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx svalových xxxxxx.
X3 BETA-2 AGONISTÉ
ZAKÁZANÉ XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx selektivní x neselektivní xxxx-2 xxxxxxxx včetně xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: maximálně xxxxxx dávka 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin;
• xxxxxxxxx vilanterol: maximálně 25 xxxxxxxxxx za 24 xxxxx.
XXXXXXXX
Xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxx xxxxxx než 1000 xx/xx nebo xxxxxxxxxxx v xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx a xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (xxxxxxxxx) xx xx výše xxxxxxx xxxxxxxxx xxxxx.
X4 XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxxx látky xx xxxxxxx X4.1 x X4.2 jsou Xxxxxxxxxx xxxxx.
Xxxxx xxxxxxxx xx xxxx X4.3 a X4.4 jsou Nespecifické xxxxx.
Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx modulátory jsou xxxxxxxx.
X4.1. XXXXXXXXXX XXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-ol) |
• |
androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx) |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. ANTIESTROGENNÍ XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. XXXXX ZABRAŇUJÍCÍ XXXXXXXX XXXXXXXXX AKTIVINU XXX
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X |
• |
xxxxxxxxxx xxxxxxxxxx, xxxx.: |
|
|
• |
xxxxxxxxxx receptoru xxxxxxxx XXX, xxxx.: |
- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx |
||
|
- xxxxxxx receptory aktivinu (xxxx. XXX-031) |
- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx myostatinu) |
|||
|
• |
protilátky xxxxx xxxxxxxxx aktivinu XXX (xxxx. bimagrumab) |
- xxxxxxxxxx neutralizující xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (PPARδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) xxxxxxxx xxxxxx (XX1516, XX501516) x xxxxxxxx Rev-erbɑ , např. SR9009, XX9011
X4.4.2 insuliny x xxxxxxxx xxxxxxxx
X4.4.3 xxxxxxxxx
X4.4.4 xxxxxxxxxxxx
X5 XXXXXXXXX X XXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx, včetně xxxxx optických xxxxxxx, xxxx. x- a x-, jsou xxxxxxxx.
Xxxx xxxx xxxxxx:
•&xxxx; Xxxxxxxxx, xxxx xxxx.:
xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx xxxxxxxxxx; furosemid; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;
• Xxxxxxx, xxxx. xxxxxxxxxx, mozavaptan, xxxxxxxxx;
• Xxxxxxxxxxx expandéry xxxxxxxx xxxxxxxxxxxx, např.:
albumin, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;
• Xxxxxxxxxxx;
• Xxxxxxxxxx;
x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
XXXXXXX
• xxxxxxxxxxx; pamabrom; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, brinzolamid);
• xxxxxxx podání xxxxxxxxxxx x zubní xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx množství látky xx stanoveným xxxxxxxx xxxxxxx: u formoterolu, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx a xxxxxxxxxxxxxx xx Xxxxxx Sportovce xxxxxxxx nebo případně Xxx Soutěži xx xxxxxxx x diuretikem xxxx jinou maskovací xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx navíc k xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX METODY
ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxxx v xxxx xxxxx xxxx Xxxxxxxxxxxx x výjimkou xxxxx v X2.2, xxx xxxx Specifické xxxxxx.
X1. MANIPULACE S XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx následující:
M1.1. Xxxxxx xxxx opětovné xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, allogenní (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx xx oběhového xxxxxxx s xxxxxxxx xxxxxxxx plazmy nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx odběrovém xxxxxx.
X1.2. Umělé xxxxxxxxx xxxxxx, xxxxxxx nebo xxxxxxx kyslíku.
Mimo xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx a modifikované xxxxxxxxxxxxx xxxxxxxx, např. xxxxxx náhražky xx xxxx hemoglobinu a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.
X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X2.1. Xxxxxxxxx xxxx Xxxxx o xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx kontrole.
Mimo jiné xxxxxx:
Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.
X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx v průběhu xxxxxxxxxxxx ošetření, chirurgických xxxxxxx nebo klinických xxxxxxxxxxxxxx xxxxxxxxx.
X3. XXXXXX X BUNĚČNÝ DOPING
Z xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:
X3.1. Použití xxxxxxxxxx xxxxxxx nebo xxxxxx analogů, xxxxx xxxxx změnit xxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx xxxx x technologie přenosů xxxx.
X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 STIMULANCIA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx x výjimkou xxxxx xxxxxxxxx v X6.X, xxx jsou Xxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: kokain x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)
Xxxxxxx xxxxxxxxxxx, včetně xxxxx xxxxxxxxx izomerů, xxxx. x- a x-, xxxx zakázána.
Stimulancia xxxxxxxx:
X6.X: XXXXXXXXXXXX STIMULANCIA
|
• |
adrafinil |
• |
fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx látkou.
S6.B: XXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, metylhexanamin) |
• |
heptaminol |
• |
pentetrazol |
||
|
• |
4-methylpentan-2-amin (1,3-dimethylbutylamin) |
• |
hydrafinil (xxxxxxxxx) |
• |
xxxxxxxxxxx x jeho xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxx1) |
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
||
|
• |
xxxxxxx x xxxx analogy, xxxx. xxxxxxxx, xxxxxxxx a ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (dimetylamfetamin) |
• |
metylendioxymetamfetamin |
• |
selegilin |
||
|
• |
efedrin3) |
• |
metylefedrin3) |
• |
sibutramin |
||
|
• |
epinefrin (xxxxxxxxx)4) |
• |
xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát] |
• |
solriamfetol |
||
|
• |
etamivan |
• |
metylfenidát |
• |
strychnin |
||
|
• |
etylfenidát |
• |
niketamid |
• |
tenamfetamin (metylendioxyamfetamin) |
||
|
• |
etylamfetamin |
• |
norfenefrin |
• |
tuaminoheptan |
||
|
• |
etilefrin |
• |
oktodrin (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky
VÝJIMKY
• klonidin;
• xxxxxxxx xxxxxxxxxxx v xxxxxxx jejich xxxxxxx, xxxxxxx, očního xxxx xxxxxx xxxxxxx (např. xxxxxxxxxx, klonazolin, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, xxxxxxxxxxxx, xxxxxxxxxx, tramazolin, xylometazolin) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 20245).
X7 XXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxx (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, včetně xxxxxx xxxxxxxxxx xxxxx optických xxxxxxx, např. d- x x, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx a jeho xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 KANABINOIDY
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx. Návykové látky x této xxxxx: xxxxxxxxxxxxxxxxxxx (THC)
Všechny přírodní x xxxxxxxxxx kanabinoidy xxxx xxxxxxxx, např.
• x xxxxxx (xxxxx, xxxxxxxxx) x konopných xxxxxxxxxx
• xxxxxxxx x xxxxxxxxxx tetrahydrokanabionoly (XXX)
• xxxxxxxxxx xxxxxxxxxxx napodobující xxxxxx XXX
XXXXXXX
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx glukokortikoidy xxxx zakázány, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (např. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx cestou.
Mimo xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx xxxxxxx podání (včetně xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx xxxxxxxxx x rámci výrobcem xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX X URČITÝCH SPORTECH
Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Při Xxxxxxx x xxx xx xx označeno xxxxxxxx (*) i Xxxx xxxxxx.
• xxxxxxxxxxx (XX)*
• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx skoky / U-rampa x xxxxxxxxx X-xxxxx / xxx air
• automobilový xxxxx (FIA)
• xxxxxxxx xxxxxx (XXXX)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx harpunou x xxxxxxx xx xxxx
• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
• xxxxx (WDF)
• xxxx (XXX)
• xxxxxxxx (XXX)
• xxxxxxx (ISSF, XXX)*
* xxxxxxxx xxxx Xxxx xxxxxx
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;
1) xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx xxxxxxxx xxxxx xxx koncentraci x xxxx vyšší xxx 5 xxxxxxxxxx x 1 ml.
2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx koncentraci x xxxx xxxxx xxx 150 mikrogramů x 1 xx.
3) efedrin x xxxxxxxxxxxx: zakázány xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 xxxxxxxxxx v 1 xx.
4) epinefrin (xxxxxxxxx): není zakázáno xxxxxxx xxxxxxxx, např. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx.
5) bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx a xxxxxxxx: tyto látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx xxxxxxxxxx xx Zakázané látky.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.
Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx předpisů x odkazech xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu